» Articles » PMID: 30353605

Genetic Evidence Implies That Primary and Relapsed Tumors Arise from Common Precursor Cells in Primary Central Nervous System Lymphoma

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare subtype of lymphoma that arises within the brain or the eyes. PCNSL recurs within the central nervous system (CNS) in most relapsed cases, whereas extra-CNS relapse is experienced in rare cases. The present study aimed at identifying the presence of common precursor cells (CPC) for primary intra- and relapsed extra-CNS tumors, and further assessing the initiating events in bone marrow (BM). Targeted deep sequencing was carried out for five paired primary intra- and relapsed extra-CNS tumors of PCNSL. Two to five mutations were shared by each pair of intra- and extra-CNS tumors. In particular, MYD88 mutations, L265P in three and P258L in one, were shared by four pairs. Unique somatic mutations were observed in all five intra-CNS tumors and in four out of five extra-CNS tumors. Remarkably, IgH clones in the intra- and the extra-CNS tumors in two pairs were distinct from each other, whereas one pair of tumors shared identical monoclonal IgH rearrangement. In a cohort of 23 PCNSL patients, L265P MYD88 mutations were examined in tumor-free BM mononuclear cells (MNC) in which the PCNSL tumors had L265P MYD88 mutations. L265P MYD88 mutations were detected by a droplet digital PCR method in nine out of 23 bone marrow mononuclear cells. These results suggest that intra- and extra-tumors are derived from CPC with MYD88 mutations in most PCNSL, arising either before or after IgH rearrangement. The initiating MYD88 mutations may occur during B-cell differentiation in BM.

Citing Articles

Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma.

Hattori K, Makishima K, Suma S, Abe Y, Suehara Y, Sakamoto T EJHaem. 2024; 5(6):1201-1214.

PMID: 39691244 PMC: 11647707. DOI: 10.1002/jha2.1046.


Clonally unrelated primary large B-cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune-privileged sites?.

George G, Aldowitz D, Jajosky A, Wallace D, Burack W, Friedberg J EJHaem. 2024; 5(3):599-602.

PMID: 38895078 PMC: 11182395. DOI: 10.1002/jha2.898.


Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.

Wilson W, Wright G, Huang D, Hodkinson B, Balasubramanian S, Fan Y Cancer Cell. 2021; 39(12):1643-1653.e3.

PMID: 34739844 PMC: 8722194. DOI: 10.1016/j.ccell.2021.10.006.


Relapsed Primary Central Nervous System Lymphoma: Current Advances.

Tao K, Wang X, Tian X Front Oncol. 2021; 11:649789.

PMID: 33996566 PMC: 8118624. DOI: 10.3389/fonc.2021.649789.


Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?.

Boiza-Sanchez M, Manso R, Balague O, Chamizo C, Askari E, Salgado R PLoS One. 2020; 15(11):e0241634.

PMID: 33180881 PMC: 7661053. DOI: 10.1371/journal.pone.0241634.


References
1.
Chung S, Kim E, Park J, Chung Y, Lito P, Teruya-Feldstein J . Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014; 6(238):238ra71. PMC: 4501573. DOI: 10.1126/scitranslmed.3008004. View

2.
Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K . The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011; 117(12):3391-401. DOI: 10.1182/blood-2010-09-302174. View

3.
Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A . Mutational analysis of primary central nervous system lymphoma. Oncotarget. 2014; 5(13):5065-75. PMC: 4148122. DOI: 10.18632/oncotarget.2080. View

4.
Fontanilles M, Marguet F, Bohers E, Viailly P, Dubois S, Bertrand P . Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017; 8(29):48157-48168. PMC: 5564634. DOI: 10.18632/oncotarget.18325. View

5.
Taoka K, Okoshi Y, Sakamoto N, Takano S, Matsumura A, Hasegawa Y . A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. Int J Hematol. 2010; 92(4):617-23. DOI: 10.1007/s12185-010-0703-9. View